Product Description
Mifeprex (mifepristone) is used, together with another medication called misoprostol, to end an early pregnancy. (Sourced from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/mifeprex-mifepristone-information)
Mechanisms of Action: GR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Estonia | Finland | France | Germany | Greece | Hong Kong | Iceland | India | Ireland | Israel | Italy | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | New Zealand | Norway | Portugal | Romania | Russia | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Ukraine | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Corcept
Company Location: MENLO PARK CA 94025
Company CEO: Joseph K. Belanoff
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Netherlands, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Endometriosis
Phase 2: Breast Cancer|Depressive Disorder|Depressive Disorder, Major|Stress Disorders, Post-Traumatic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT06099769 | P2 |
Recruiting |
Breast Cancer |
2027-10-01 |
|
| REVERSE | P2 |
Recruiting |
Stress Disorders, Post-Traumatic |
2026-09-15 |
|
| RESET-medication | P2 |
Active, not recruiting |
Depressive Disorder |
2024-10-05 |
|
| RESET-m | P2 |
Completed |
Depressive Disorder, Major |
2024-08-09 |